Bhaven N Sampat

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. pmc Polymorphs and prodrugs and salts (oh my!): an empirical analysis of "secondary" pharmaceutical patents
    Amy Kapczynski
    Yale Law School, Yale University, New Haven, Connecticut, United States of America
    PLoS ONE 7:e49470. 2012
  2. pmc New evidence on the allocation of NIH funds across diseases
    Bhaven N Sampat
    Mailman School of Public Health, Columbia University
    Milbank Q 91:163-85. 2013
  3. ncbi request reprint Intellectual property. Challenges to India's pharmaceutical patent laws
    Bhaven N Sampat
    Health Policy and Management, Columbia University, New York, NY 10032, USA
    Science 337:414-5. 2012
  4. pmc Academic patents and access to medicines in developing countries
    Bhaven N Sampat
    Department of Health Policy and Management, the International Center for Health Outcomes and Innovation Research, School of International and Public Affairs, Columbia University, 600 West 168th St, 7th Floor, New York, NY 10032, USA
    Am J Public Health 99:9-17. 2009
  5. doi request reprint What are the respective roles of the public and private sectors in pharmaceutical innovation?
    Bhaven N Sampat
    Department of Health Policy and Management, School of Public Health, Columbia University, New York City, NY, USA
    Health Aff (Millwood) 30:332-9. 2011
  6. ncbi request reprint How do public health safeguards in Indian patent law affect pharmaceutical patenting in practice?
    Bhaven N Sampat
    Columbia University, USA
    J Health Polit Policy Law 38:735-55. 2013

Collaborators

Detail Information

Publications6

  1. pmc Polymorphs and prodrugs and salts (oh my!): an empirical analysis of "secondary" pharmaceutical patents
    Amy Kapczynski
    Yale Law School, Yale University, New Haven, Connecticut, United States of America
    PLoS ONE 7:e49470. 2012
    ..Characterizing the landscape of secondary patents is important in light of recent court decisions in the U.S. that may make them more difficult to obtain, and for developing countries considering restrictions on secondary patents...
  2. pmc New evidence on the allocation of NIH funds across diseases
    Bhaven N Sampat
    Mailman School of Public Health, Columbia University
    Milbank Q 91:163-85. 2013
    ....
  3. ncbi request reprint Intellectual property. Challenges to India's pharmaceutical patent laws
    Bhaven N Sampat
    Health Policy and Management, Columbia University, New York, NY 10032, USA
    Science 337:414-5. 2012
  4. pmc Academic patents and access to medicines in developing countries
    Bhaven N Sampat
    Department of Health Policy and Management, the International Center for Health Outcomes and Innovation Research, School of International and Public Affairs, Columbia University, 600 West 168th St, 7th Floor, New York, NY 10032, USA
    Am J Public Health 99:9-17. 2009
    ..I provide empirical evidence regarding these issues and explore the feasibility and desirability of proposals to change university patenting and licensing practices to promote access to medicines in the developing world...
  5. doi request reprint What are the respective roles of the public and private sectors in pharmaceutical innovation?
    Bhaven N Sampat
    Department of Health Policy and Management, School of Public Health, Columbia University, New York City, NY, USA
    Health Aff (Millwood) 30:332-9. 2011
    ..Our analyses should help inform thinking about the returns on public research funding-a topic of long-standing interest to economists, policy makers, and health advocates...
  6. ncbi request reprint How do public health safeguards in Indian patent law affect pharmaceutical patenting in practice?
    Bhaven N Sampat
    Columbia University, USA
    J Health Polit Policy Law 38:735-55. 2013
    ..We find that having the 3(d) provision on the books does not translate into very different patent outcomes in practice in India, relative to Europe, a jurisdiction without this provision. ..